Binding of SH2-B Family Members within a Potential Negative Regulatory Region Maintains JAK2 in an Active State

REFERENCES

• Brown, R. J., J. J. Adams, R. A. Pelekanos, Y. Wan, W. J. McKinstry, K. Palethorpe, R. M. Seeber, T. A. Monks, K. A. Eidne, M. W. Parker, and M. J. Waters. 2005. Model for growth hormone receptor activation based on subunit rotation within a receptor dimer. Nat. Struct. Mol. Biol. 12:814–821.
   PubMed Web of Science ®Google Scholar
• Chen, C., and H. Okayama. 1987. High-efficiency transformation of mammalian cells by plasmid DNA. Mol. Cell. Biol. 7:2745–2752.
   PubMed Web of Science ®Google Scholar
• Darnell, J. E., Jr., I. M. Kerr, and G. R. Stark. 1994. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 264:1415–1421.
   PubMed Web of Science ®Google Scholar
• Dhe-Paganon, S., E. D. Werner, M. Nishi, L. Hansen, Y. I. Chi, and S. E. Shoelson. 2004. A phenylalanine zipper mediates APS dimerization. Nat. Struct. Mol. Biol. 11:968–974.
   PubMedGoogle Scholar
• Duan, C., H. Yang, M. F. White, and L. Rui. 2004. Disruption of SH2-B causes age-dependent insulin resistance and glucose intolerance. Mol. Cell. Biol. 24:743507443.
   Google Scholar
• Feng, J., B. A. Witthuhn, T. Matsuda, F. Kohlhuber, I. M. Kerr, and J. N. Ihle. 1997. Activation of Jak2 catalytic activity requires phosphorylation of Y1007 in the kinase activation loop. Mol. Cell. Biol. 17:2497–2501.
   PubMed Web of Science ®Google Scholar
• Frank, S. J., G. Gilliland, A. S. Kraft, and C. S. Arnold. 1994. Interaction of the growth hormone receptor cytoplasmic domain with the JAK2 tyrosine kinase. Endocrinology 135:2228–2239.
   PubMedGoogle Scholar
• Frank, S. J., W. Yi, Y. Zhao, J. F. Goldsmith, G. Gilliland, J. Jiang, I. Sakai, and A. S. Kraft. 1995. Regions of the JAK2 tyrosine kinase required for coupling to the growth hormone receptor. J. Biol. Chem. 270:14776–14785.
   PubMedGoogle Scholar
• Higgins, D. G., J. D. Thompson, and T. J. Gibson. 1996. Using CLUSTAL for multiple sequence alignments. Methods Enzymol. 266:383–402.
   PubMed Web of Science ®Google Scholar
• Hu, J., J. Liu, R. Ghirlando, A. R. Saltiel, and S. R. Hubbard. 2003. Structural basis for recruitment of the adapter protein APS to the activated insulin receptor. Mol. Cell 12:1379–1389.
   PubMed Web of Science ®Google Scholar
• Huang, X., Y. Li, K. Tanaka, K. G. Moore, and J. I. Hayashi. 1995. Cloning and characterization of Lnk, a signal transduction protein that links T-cell receptor activation signal to phospholipase C γ 1, Grb2, and phosphatidylinositol 3-kinase. Proc. Natl. Acad. Sci. USA 92:11618–11622.
   PubMed Web of Science ®Google Scholar
• Iseki, M., S. Takaki, and K. Takatsu. 2000. Molecular cloning of the mouse APS as a member of the Lnk family adaptor proteins. Biochem. Biophys. Res. Commun. 272:45–54.
   PubMedGoogle Scholar
• Kotani, K., P. Wilden, and T. S. Pillay. 1998. SH2-Bα is an insulin-receptor adapter protein and substrate that interacts with the activation loop of the insulin-receptor kinase. Biochem. J. 335:103–109.
   PubMedGoogle Scholar
• Kralovics, R., F. Passamonti, A. S. Buser, S. S. Teo, R. Tiedt, J. R. Passweg, A. Tichelli, M. Cazzola, and R. C. Skoda. 2005. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N. Engl. J. Med. 352:1779–1790.
   PubMed Web of Science ®Google Scholar
• Kurzer, J. H., L. S. Argetsinger, Y.-J. Zhou, J.-L. Kouadio, J. J. O'Shea, and C. Carter-Su. 2004. Tyrosine 813 is a site of JAK2 autophosphorylation critical for activation of JAK2 by SH2-Bβ. Mol. Cell. Biol. 24:4557–4570.
   PubMed Web of Science ®Google Scholar
• Lacronique, V., A. Boureux, V. D. Valle, H. Poirel, C. T. Quang, M. Mauchauffe, C. Berthou, M. Lessard, R. Berger, J. Ghysdael, and O. A. Bernard. 1997. A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia. Science 278:1309–1312.
   PubMed Web of Science ®Google Scholar
• Leonard, W. J., and J. J. O'Shea. 1998. Jaks and STATs: biological implications. Annu. Rev. Immunol. 16:293–322.
   PubMed Web of Science ®Google Scholar
• Levine, R. L., M. Wadleigh, J. Cools, B. L. Ebert, G. Wernig, B. J. Huntly, T. J. Boggon, I. Wlodarska, J. J. Clark, S. Moore, J. Adelsperger, S. Koo, J. C. Lee, S. Gabriel, T. Mercher, A. D'Andrea, S. Frohling, K. Dohner, P. Marynen, P. Vandenberghe, R. A. Mesa, A. Tefferi, J. D. Griffin, M. J. Eck, W. R. Sellers, M. Meyerson, T. R. Golub, S. J. Lee, and D. G. Gilliland. 2005. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 7:387–397.
   PubMed Web of Science ®Google Scholar
• Li, M., D. Ren, M. Iseki, S. Takaki, and L. Rui. 2006. Differential role of SH2-B and APS in regulating energy and glucose homeostasis. Endocrinology 147:2163–2170.
   PubMed Web of Science ®Google Scholar
• Liu, B. P., and K. Burridge. 2000. Vav2 activates Rac1, Cdc42, and RhoA downstream from growth factor receptors but not β1 integrins. Mol. Cell. Biol. 20:7160–7169.
   PubMed Web of Science ®Google Scholar
• Lucet, I. S., E. Fantino, M. Styles, R. Bamert, O. Patel, S. E. Broughton, M. Walter, C. J. Burns, H. Treutlein, A. F. Wilks, and J. Rossjohn. 2006. The structural basis of Janus kinase 2 inhibition by a potent and specific pan-Janus kinase inhibitor. Blood 107:176–183.
   PubMed Web of Science ®Google Scholar
• Minami, A., M. Iseki, K. Kishi, M. Wang, M. Ogura, N. Furukawa, S. Hayashi, M. Yamada, T. Obata, Y. Takeshita, Y. Nakaya, Y. Bando, K. Izumi, S. A. Moodie, F. Kajiura, M. Matsumoto, K. Takatsu, S. Takaki, and Y. Ebina. 2003. Increased insulin sensitivity and hypoinsulinemia in APS knockout mice. Diabetes 52:2657–2665.
   PubMedGoogle Scholar
• Moodie, S. A., J. Alleman-Sposeto, and T. A. Gustafson. 1999. Identification of the APS protein as a novel insulin receptor substrate. J. Biol. Chem. 274:11186–11193.
   PubMedGoogle Scholar
• Nelms, K., T. J. O'Neill, S. Li, S. R. Hubbard, T. A. Gustafson, and W. E. Paul. 1999. Alternative splicing, gene localization, and binding of SH2-B to the insulin receptor kinase domain. Mamm. Genome 10:1160–1167.
   PubMed Web of Science ®Google Scholar
• Nishi, M., E. D. Werner, B. C. Oh, J. D. Frantz, S. Dhe-Paganon, L. Hansen, J. Lee, and S. E. Shoelson. 2005. Kinase activation through dimerization by human SH2-B. Mol. Cell. Biol. 25:2607–2621.
   PubMedGoogle Scholar
• O'Brien, K. B., L. S. Argetsinger, M. Diakonova, and C. Carter-Su. 2003. YXXL motifs in SH2-Bβ are phosphorylated by JAK2, JAK1, and platelet-derived growth factor receptor and are required for membrane ruffling. J. Biol. Chem. 278:11970–11978.
   PubMed Web of Science ®Google Scholar
• O'Brien, K. B., J. J. O'Shea, and C. Carter-Su. 2002. SH2-B family members differentially regulate JAK family tyrosine kinases. J. Biol. Chem. 277:8673–8681.
   PubMedGoogle Scholar
• Ohtsuka, S., S. Takaki, M. Iseki, K. Miyoshi, N. Nakagata, Y. Kataoka, N. Yoshida, K. Takatsu, and A. Yoshimura. 2002. SH2-B is required for both male and female reproduction. Mol. Cell. Biol. 22:3066–3077.
   PubMedGoogle Scholar
• Osborne, M. A., S. Dalton, and J. P. Kochan. 1995. The yeast tribrid system—genetic detection of trans-phosphorylated ITAM-SH2-interactions. Bio/Technology 13:1474–1478.
   PubMedGoogle Scholar
• O'Shea, J. J., M. Gadina, and R. D. Schreiber. 2002. Cytokine signaling in 2002: new surprises in the Jak/Stat pathway. Cell 109(Suppl.):S121–S131.
   PubMed Web of Science ®Google Scholar
• Peeters, P., S. D. Raynaud, J. Cools, I. Wlodarska, J. Grosgeorge, P. Philip, F. Monpoux, L. Van Rompaey, M. Baens, H. Van den Berghe, and P. Marynen. 1997. Fusion of TEL, the ETS-variant gene 6 (ETV6), to the receptor-associated kinase JAK2 as a result of t(9;12) in a lymphoid and t(9;15:12) in a myeloid leukemia. Blood 90:2535–2540.
   PubMed Web of Science ®Google Scholar
• Qian, X., and D. D. Ginty. 2001. SH2-B and APS are multimeric adapters that augment TrkA signaling. Mol. Cell. Biol. 21:1613–1620.
   PubMed Web of Science ®Google Scholar
• Qian, X., A. Riccio, Y. Zhang, and D. D. Ginty. 1998. Identification and characterization of novel substrates of Trk receptors in developing neurons. Neuron 21:1017–1029.
   PubMed Web of Science ®Google Scholar
• Ren, D., M. Li, C. Duan, and L. Rui. 2005. Identification of SH2-B as a key regulator of leptin sensitivity, energy balance and body weight in mice. Cell Metab. 2:95–104. [Online.] 10.1016/j.cmet.2005.07.004.
   PubMed Web of Science ®Google Scholar
• Rui, L., and C. Carter-Su. 1999. Identification of SH2-Bβ as a potent cytoplasmic activator of the tyrosine kinase Janus kinase 2. Proc. Natl. Acad. Sci. USA 96:7172–7177.
   PubMedGoogle Scholar
• Rui, L., D. R. Gunter, J. Herrington, and C. Carter-Su. 2000. Differential binding to and regulation of JAK2 by the SH2 domain and N-terminal region of SH2-Bβ. Mol. Cell. Biol. 20:3168–3177.
   PubMedGoogle Scholar
• Rui, L., L. S. Mathews, K. Hotta, T. A. Gustafson, and C. Carter-Su. 1997. Identification of SH2-Bβ as a substrate of the tyrosine kinase JAK2 involved in growth hormone signaling. Mol. Cell. Biol. 17:6633–6644.
   PubMed Web of Science ®Google Scholar
• Russell, S. M., J. A. Johnston, M. Noguchi, M. Kawamura, C. M. Bacon, M. Friedmann, M. Berg, D. W. McVicar, B. A. Witthuhn, and O. Silvennoinen. 1994. Interaction of IL-2R beta and gammac chains with Jak1 and Jak3: implications for XSCID and XCID. Science 266:1042–1045.
   PubMed Web of Science ®Google Scholar
• Saharinen, P., and O. Silvennoinen. 2002. The pseudokinase domain is required for suppression of basal activity of Jak2 and Jak3 tyrosine kinases and for cytokine-inducible activation of signal transduction. J. Biol. Chem. 277:47954–47963.
   PubMed Web of Science ®Google Scholar
• Saharinen, P., K. Takaluoma, and O. Silvennoinen. 2000. Regulation of the Jak2 tyrosine kinase by its pseudokinase domain. Mol. Cell. Biol. 20:3387–3395.
   PubMed Web of Science ®Google Scholar
• Saharinen, P., M. Vihinen, and O. Silvennoinen. 2003. Autoinhibition of Jak2 tyrosine kinase is dependent on specific regions in its pseudokinase domain. Mol. Biol. Cell 14:1448–1459.
   PubMedGoogle Scholar
• Silvennoinen, O., B. Witthuhn, F. W. Quelle, J. L. Cleveland, T. Yi, and J. N. Ihle. 1993. Structure of the murine JAK2 protein-tyrosine kinase and its role in interleukin 3 signal transduction. Proc. Natl. Acad. Sci. USA 90:8429–8433.
   PubMed Web of Science ®Google Scholar
• Starr, R., T. A. Willson, E. M. Viney, L. J. Murray, J. R. Rayner, B. J. Jenkins, T. J. Gonda, W. S. Alexander, D. Metcalf, N. A. Nicola, and D. J. Hilton. 1997. A family of cytokine-inducible inhibitors of signalling. Nature 387:917–921.
   PubMed Web of Science ®Google Scholar
• Tong, W., J. Zhang, and H. F. Lodish. 2005. Lnk inhibits erythropoiesis and Epo-dependent JAK2 activation and downstream signaling pathways. Blood 105:4604–4612.
   PubMed Web of Science ®Google Scholar
• Uhlik, M. T., B. Temple, S. Bencharit, A. J. Kimple, D. P. Siderovski, and G. L. Johnson. 2005. Structural and evolutionary division of phosphotyrosine binding (PTB) domains. J. Mol. Biol. 345:1–20.
   PubMedGoogle Scholar
• Wakioka, T., A. Sasaki, K. Mitsui, M. Yokouchi, A. Inoue, S. Komiya, and A. Yoshimura. 1999. APS, an adaptor protein containing Pleckstrin homology (PH) and Src homology-2 (SH2) domains inhibits the JAK-STAT pathway in collaboration with c-Cbl. Leukemia 13:760–767.
   PubMed Web of Science ®Google Scholar
• Wilks, A. F., A. G. Harpur, R. R. Kurban, S. J. Ralph, G. Zurcher, and A. Ziemiecki. 1991. Two novel protein-tyrosine kinases, each with a second phosphotransferase-related catalytic domain, define a new class of protein kinase. Mol. Cell. Biol. 11:2057–2065.
   PubMed Web of Science ®Google Scholar
• Yamaoka, K., P. Saharinen, M. Pesu, V. E. Holt III, O. Silvennoinen, and J. J. O'Shea. 2004. The Janus kinases (Jaks). Genome Biol. 5:253–256.
   PubMed Web of Science ®Google Scholar
• Yasukawa, H., H. Misawa, H. Sakamoto, M. Masuhara, A. Sasaki, T. Wakioka, S. Ohtsuka, T. Imaizumi, T. Matsuda, J. N. Ihle, and A. Yoshimura. 1999. The JAK-binding protein JAB inhibits Janus tyrosine kinase activity through binding in the activation loop. EMBO J. 18:1309–1320.
   PubMed Web of Science ®Google Scholar
• Yokouchi, M., R. Suzuki, M. Masuhara, S. Komiya, A. Inoue, and A. Yoshimura. 1997. Cloning and characterization of APS, an adaptor molecule containing PH and SH2 domains that is tyrosine phosphorylated upon B-cell receptor stimulation. Oncogene 15:7–15.
   PubMedGoogle Scholar
• Yousaf, N., Y. Deng, Y. Kang, and H. Riedel. 2001. Four PSM/SH2-B alternative splice variants and their differential roles in mitogenesis. J. Biol. Chem. 276:40940–40948.
   PubMed Web of Science ®Google Scholar
• Zhao, R., S. Xing, Z. Li, X. Fu, Q. Li, S. B. Krantz, and Z. J. Zhao. 2005. Identification of an acquired JAK2 mutation in polycythemia vera. J. Biol. Chem. 280:22788–22792.
   PubMed Web of Science ®Google Scholar
• Zhou, Y. J., M. Chen, N. A. Cusack, L. H. Kimmel, K. S. Magnuson, J. G. Boyd, W. Lin, J. L. Roberts, A. Lengi, R. H. Buckley, R. L. Geahlen, F. Candotti, M. Gadina, P. S. Changelian, and J. J. O'Shea. 2001. Unexpected effects of FERM domain mutations on catalytic activity of Jak3: structural implication for Janus kinases. Mol. Cell 8:959–969.
   PubMed Web of Science ®Google Scholar
• Zhou, Y. J., E. P. Hanson, Y. Q. Chen, K. Magnuson, M. Chen, P. G. Swann, R. L. Wange, P. S. Changelian, and J. J. O'Shea. 1997. Distinct tyrosine phosphorylation sites in JAK3 kinase domain positively and negatively regulate its enzymatic activity. Proc. Natl. Acad. Sci. USA 94:13850–13855.
   PubMed Web of Science ®Google Scholar